Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
October 02 2023 - 8:00AM
Business Wire
Collaboration with CardioNXT provides navigation and mapping
system integration with Pulse Biosciences’ nsPFA circumferential
catheter to support first-in-human treatments
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company
primarily focused on leveraging its novel and proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology for the
treatment of atrial fibrillation, today announced a collaboration
with CardioNXT, to support Pulse Biosciences’ planned nsPFA cardiac
catheter first-in-human study focused on the treatment of atrial
fibrillation.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231002712863/en/
Seamless integration of Pulse
Biosciences’ nsPFA cardiac circumferential catheter and CardioNXT’s
3D iMap navigation and mapping system. (1) nsPFA cardiac
circumferential catheter, (2) nsPFA cardiac circumferential
catheter visualized by iMap, (3) Electroanatomical map of the left
atrium using the iMap system and the Pulse circumferential
catheter. Courtesy of Jacob Koruth, MD, and Iwanari Kawamura,
MD.
“We are excited to announce this collaboration and the progress
we’ve made integrating our circumferential nsPFA catheter with the
CardioNXT iMap System,” said Kevin Danahy, Chief Executive Officer
of Pulse Biosciences. “The CardioNXT navigation and mapping system
was our top choice for integration with our novel nsPFA cardiac
circumferential catheter. Their iMap system offers dynamic
referencing to provide superior accuracy and stability when
navigating our catheter to targeted tissue areas. We’re on track to
initiate our first-in-human study in the first half of next year
and believe this combination has the potential to achieve
best-in-class clinical outcomes.”
The collaboration will include full integration of Pulse
Biosciences’ nsPFA circumferential cardiac catheter and CardioNXT’s
iMap Navigation and Mapping System, enabling electrophysiologists
to successfully visualize individual cardiac structures and place
the nsPFA catheter for circumferential ablations of targeted
pulmonary veins in the treatment of atrial fibrillation.
“We are excited to partner with Pulse Biosciences to advance our
shared mission of improving cardiac therapy while further
demonstrating the versatility of iMap. Pulse’s nsPFA technology
provides a highly differentiated catheter-based solution and the
integration with our system has the potential to provide fast,
accurate, effective, and safe zero-fluoro ablation of cardiac
tissue for the treatment of AF,” said Jerome Edwards, Chief
Executive Officer of CardioNXT.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation and in a select few other markets
where nsPFA could have a profound positive impact on healthcare for
both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
About CardioNXT, Inc.
CardioNXT has developed a commercially available 3D Mapping
& Navigation System that leverages internal navigation
referencing with electromagnetic tracking and AI enabled complex
mapping algorithms. The CardioNXT Team has a track record of
creating market leading 3D Navigation & Mapping products such
as the Medtronic-StealthStation, Medtronic-LocaLisa, and
Olympus-Veran Systems which have enjoyed market leadership
positions in multiple clinical applications.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002712863/en/
Pulse Biosciences Kevin Danahy, President and CEO 510.241.1077
IR@pulsebiosciences.com or Gilmartin Group Philip Trip Taylor
415.937.5406 philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024